Lowering total plasma insulin-like growth factor I concentrations by way of a novel, potent, and selective growth hormone (GH) receptor antagonist, pegvisomant (B2036-peg), augments the amplitude of GH secretory bursts and elevates basal/nonpulsatile GH release in healthy women and men.

Source:http://linkedlifedata.com/resource/pubmed/id/11443205

Download in:

View as

General Info

PMID
11443205